BNP Paribas Financial Markets’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,104
| Closed | -$118K | – | 5979 |
|
|
2025
Q3 | $118K | Sell |
1,104
-175,048
| -99% | -$18.3M | ﹤0.01% | 4222 |
|
|
2025
Q2 | $16.7M | Buy |
176,152
+166,224
| +1,674% | +$12.3M | 0.01% | 1137 |
|
|
2025
Q1 | $630K | Sell |
9,928
-5,812
| -37% | -$348K | ﹤0.01% | 3047 |
|
|
2024
Q4 | $731K | Sell |
15,740
-44,471
| -74% | -$1.67M | ﹤0.01% | 3038 |
|
|
2024
Q3 | $1.73M | Buy |
60,211
+38,434
| +176% | +$946K | ﹤0.01% | 2133 |
|
|
2024
Q2 | $315K | Sell |
21,777
-1,635
| -7% | -$23.9K | ﹤0.01% | 2893 |
|
|
2024
Q1 | $377K | Buy |
23,412
+21,384
| +1,054% | +$370K | ﹤0.01% | 2992 |
|
|
2023
Q4 | $40.3K | Buy |
2,028
+1,128
| +125% | +$16.7K | ﹤0.01% | 3600 |
|
|
2023
Q3 | $14.7K | Sell |
900
-13,860
| -94% | -$267K | ﹤0.01% | 3592 |
|
|
2023
Q2 | $312K | Buy |
14,760
+3,778
| +34% | +$80.6K | ﹤0.01% | 2832 |
|
|
2023
Q1 | $221K | Buy |
10,982
+10,560
| +2,502% | +$228K | ﹤0.01% | 3110 |
|
|
2022
Q4 | $11K | Buy |
+422
| New | +$5.62K | ﹤0.01% | 3606 |
|
|
2022
Q1 | – | Sell |
-238
| Closed | -$1.6K | – | 4387 |
|
|
2021
Q4 | $1.6K | Buy |
+238
| New | +$1.22K | ﹤0.01% | 4018 |
|
Other funds holding VRNA
BNP Paribas Financial Markets's VRNA Position: Q4 2025 in Review
BNP Paribas Financial Markets sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,104 shares — an estimated $118K sold.
BNP Paribas Financial Markets first reported a position in VRNA in Q4 2021 and held it in 13 quarters. The position peaked at $16.7M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.
- BNP Paribas Financial Markets reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
- BNP Paribas Financial Markets sold 1,104 Verona Pharma shares in Q4 2025, an estimated $118K.
- BNP Paribas Financial Markets first reported a position in Verona Pharma in Q4 2021 and held it in 13 quarters.
- BNP Paribas Financial Markets's Verona Pharma position peaked at $16.7M in Q2 2025.
- 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2025, filed 10 Feb 2026.